18 completed, 5 recruiting, 5 terminated, 5 unknown. 10 Not applicable, 8 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 10 | Completed 8, Terminated 1, Unknown 1 |
| Phase 2 | 8 | Completed 3, Recruiting 3, Terminated 2 |
| Phase 1 | 6 | Completed 5, Terminated 1 |
| Phase 3 | 2 | Not yet recruiting 1, Terminated 1 |
Follow Protozoan Infections, Animal: new trials by email Literature Review of Protozoan Infections, Animal trials Research Report on Protozoan Infections, Animal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nitazoxanide for Treatment of Cryptosporidium in Children Nitazoxanide, Placebo - Cryptosporidiosis | Phase 3 | Not yet recruiting | Johns Hopkins Bloomberg School of Public Health | 480 | 2026-12-30 | 2026-09-28 |
| The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children Echinacea Extract - Cryptosporidium Infection | Phase 2 | Recruiting | Al-Azhar University | 60 | 2026-01-18 | 2026-02-05 |
| A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric Participants Cryptosporidiosis | Recruiting | Novartis Pharmaceuticals | 30 | 2026-01-09 | 2026-07-21 | |
| Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults Cryptosporidium parvum oocysts (ABO809), EDI048, Placebo - Cryptosporidiosis | Phase 2 | Recruiting | Novartis Pharmaceuticals | 80 | 2025-12-08 | 2026-08-19 |
| Human Babesiosis in Metropolitan France Human Babesiosis | Recruiting | University Hospital, Strasbourg, France | 100 | 2025-11-04 | 2026-01-16 | |
| Blastocystis and Cryptosporidium Infection in Colorectal Cancer Patients ELISA / PCR - Blastocystis Infection, Cryptosporidium Infection | Unknown | Assiut University | 54 | 2024-11-01 | 2024-04-23 | |
| Surveillance of Emerging Pathogens to Ensure Blood Supply Safety Babesia NAT - Babesioses, Human | Withdrawn | Canadian Blood Services | 2024-10-02 | 2025-08-14 | ||
| Cryptosporidiosis and Enteropathogens in Bangladesh Cryptosporidiosis | Active not recruiting | University of Virginia | 150 | 2024-10-01 | 2025-03-30 | |
| Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis Tafenoquine, Placebo - Babesiosis | Phase 2 | Recruiting | 60 Degrees Pharmaceuticals LLC | 33 | 2024-06-17 | 2025-11-21 |
| Study of Efficacy and Safety of ABO809 in Healthy Participants Cryptosporidium parvum oocysts (ABO809) - Cryptosporidium Infection, Cryptosporidiosis | Phase 1 | Completed | Novartis Pharmaceuticals | 30 | 2022-04-07 | 2024-10-02 |
| Cryptosporidium Species in Sohag Governorate Cryptosporidiosis | Unknown | Sohag University | 200 | 2022-03-01 | 2024-04-17 | |
| Description of Case of Infection With a New Species of Babesia and Its Molecular Diagnosis Babesiosis, Human | Unknown | University Hospital, Strasbourg, France | 1 | 2021-07-10 | 2021-07-23 | |
| Cryptosporidium Infection and Human Colorectal Cancer Detection of Cryptosporidium infection - Colonic Neoplasms, Cryptosporidiosis | Unknown | Lille Catholic University | 324 | 2020-06-30 | 2023-11-18 | |
| Treatment of Cryptosporidiosis Nitazoxanide with Lactobacillus Reuteri DSM 17938, Nitazoxanide - Cryptosporidiosis | Not applicable | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 64 | 2020-02-01 | 2023-10-16 |
| Intestinal Parasites in Inhabitants of Kuyavian-Pomeranian Province in Poland Tests for diagnosis of intestinal parasitic diseases - Intestinal Disease, Parasitic, Chronic Disease | Completed | Nicolaus Copernicus University | 22 | 2018-02-17 | 2020-03-26 | |
| A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Clofazimine, Placebo - Cryptosporidiosis | Phase 2 | Terminated | University of Washington | 33 | 2017-12-14 | 2019-08-13 |
| Trial of Ceramic Water Filters to Reduce Cryptosporidium Infection in Kenya Ceramic water filter - Cryptosporidium; Diarrhea, Cryptosporidiosis | Not applicable | Completed | Centers for Disease Control and Prevention | 227 | 2013-01-01 | 2017-03-22 |
| Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events HIV, Malnutrition | Completed | Cornell University | 208 | 2012-04-01 | 2017-11-01 | |
| Transmission and the Respiratory Tract in Cryptosporidiosis Cryptosporidiosis | Completed | Tufts University | 480 | 2007-10-01 | 2009-12-03 | |
| Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients Nitazoxanide - Cryptosporidiosis, HIV Infections | Phase 3 | Terminated | Romark Laboratories L.C. | 30 | 2000-02-01 | 2005-06-24 |
Showing 20 of 36. Sign in to see all of them.
Cryptosporidiosis (32) · HIV Infections (16) · Acquired Immunodeficiency Syndrome (11) · Diarrhea (10) · AIDS-Related Opportunistic Infections (8) · Babesiosis (4) · Echinococcosis (2) · Giardiasis (2) · Intestinal Diseases, Parasitic (2) · Trichinellosis (2) · Amebiasis (1) · Ascariasis (1) · Blastocystis Infections (1) · Cestode Infections (1) · Chronic Disease (1)
Animal Diseases (36) · Parasitic Diseases, Animal (36) · Protozoan Infections (36) · Infections (35) · Parasitic Diseases (35) · Digestive System Diseases (32) · Gastrointestinal Diseases (32) · Intestinal Diseases (32) · Coccidiosis (31) · Intestinal Diseases, Parasitic (30) · Blood-Borne Infections (16) · Communicable Diseases (16) · Genital Diseases (16) · Immune System Diseases (16)
nitazoxanide (6) · Azithromycin (3) · Interleukin-12 (2) · Paromomycin (2) · Spiramycin (2) · diclazuril (2) · Clofazimine (1) · Echinacea extract (1) · letrazuril (1) · tafenoquine (1)
National Institute of Allergy and Infectious Diseases (NIAID) (7) · Novartis Pharmaceuticals (3) · Janssen, LP (2) · Pfizer (2) · Rhone-Poulenc Rorer (2) · Romark Laboratories L.C. (2) · University Hospital, Strasbourg, France (2) · 60 Degrees Pharmaceuticals LLC (1) · Al-Azhar University (1) · Assiut University (1) · Canadian Blood Services (1) · Centers for Disease Control and Prevention (1) · Cornell University (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Johns Hopkins Bloomberg School of Public Health (1)
United States (18) · France (3) · Bangladesh (2) · Egypt (2) · Kenya (2) · Malawi (1) · Malaysia (1) · Poland (1) · Puerto Rico (1) · South Africa (1) · Tanzania (1) · Thailand (1) · Uganda (1) · Zambia (1)
A. Clinton White (1) · Arthur White (1) · Bertrand Nunes, MD (1) · Carey J (1) · Carmen L Charlton, PhD (1) · Eric Mintz, MD, MPH (1) · Fichtenbaum C (1) · Gabriela Certad, MD, PhD (1) · Jeffrery K Griffiths, MD (1) · Mindy Goldman, MD (1) · Mohamed Al-Ibrahim (1) · Moskovitz BL (1) · Myron Levin, MD (1)
PMID 20377408, PMID 30139372, PMID 32277809, PMID 34748385, PMID 37832036, PMID 40488529, PMID 42201116
R01AI041735 (1), R01AI043596 (1), U01AI167788 (1)